抗中性粒细胞胞浆抗体相关血管炎的治疗：新疗法及对旧有疾病的审视
Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
作者信息
Zand Ladan, Specks Ulrich, Sethi Sanjeev, Fervenza Fernando C
机构信息
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN.
出版信息
Adv Chronic Kidney Dis. 2014 Mar;21(2):182-93. doi: 10.1053/j.ackd.2014.01.009.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a small-vessel vasculitis that primarily comprises 2 clinical syndromes: granulomatosis with polyangiitis and microscopic polyangiitis. Cyclophosphamide and glucocorticoids have traditionally been used for induction of remission. However, more recent studies have shown that rituximab is as effective as cyclophosphamide for induction therapy in patients with newly diagnosed severe AAV and superior for patients with relapsing AAV. There is also accumulating evidence indicating a potential role of rituximab for maintenance therapy in AAV. In this article, we will review the evidence supporting the various treatment choices for patients with AAV.
抗中性粒细胞胞浆抗体（ANCA）相关血管炎（AAV）是一种小血管炎，主要包括两种临床综合征：肉芽肿性多血管炎和显微镜下多血管炎。传统上，环磷酰胺和糖皮质激素用于诱导缓解。然而，最近的研究表明，利妥昔单抗在新诊断的重症AAV患者的诱导治疗中与环磷酰胺一样有效，而在复发型AAV患者中效果更佳。也有越来越多的证据表明利妥昔单抗在AAV维持治疗中具有潜在作用。在本文中，我们将综述支持AAV患者各种治疗选择的证据。
Zotero 插件